(a)
(b)
(c)
(d)
(e)
(f)
Figure 3: RSG attenuated sevoflurane-induced cognitive impairment in 6-day-old mice. (a) Sevoflurane downregulated the protein levels of PPAR-γ, and rosiglitazone (RSG) attenuated this decrease in PPAR-γ levels in 6-day-old mice. (b) Quantification of western blots confirmed that RSG attenuated the sevoflurane-induced decrease in the protein levels of PPAR-γ (). (c) Daily treatment of P6 mice with RSG for 3 days did not increase the escape latency of mice in the MWM at P30–P34 (control: ; RSG: ). (d) RSG treatment did not reduce the platform crossing times of mice at P34 (control: ; RSG: ). (e) Results from two-way ANOVA with repeated measurement analysis showed that there was a statistically significant interaction between time and group (sevoflurane: ; sevoflurane + RSG: ). (f) The Mann-Whitney test showed that there was a significant difference in platform crossing times between sevoflurane-treated mice and sevoflurane + RSG-treated mice (sevoflurane: ; sevoflurane + RSG: ).